Add-on Acquisition • Chemicals

Bayer Acquires Laboratorios BIAGRO S.A.

On March 6, 2014, Bayer acquired chemicals company Laboratorios BIAGRO S.A.

Acquisition Context
  • This is Bayer’s 2nd transaction in the Chemicals sector.
  • This is Bayer’s 1st transaction in Argentina.

Explore All 1513 Add-on Acquisition Chemicals Deals - Search the Database Free


M&A Deal Summary

Date March 6, 2014
Target Laboratorios BIAGRO S.A.
Sector Chemicals
Buyer(s) Bayer
Deal Type Add-on Acquisition

Target Company

Laboratorios BIAGRO S.A.

Las Heras, Argentina
Laboratorios BIAGRO S.A. is a manufacturer of legume inoculants and also products for integrated pest management.
Explore More Deals

Browse All 215,156 Deals

FILTER BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Search Free

Buyer Overview 1

Buyer

Bayer

Leverkusen, Germany

Category Company
Founded 1863
Sector Life Science
Employees89,556
Revenue 46.6B EUR (2024)
DESCRIPTION
Bayer office building in North Sydney, Australia.
Bayer office building in North Sydney, Australia.

Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech polymer materials. As an innovation company, it sets trends in research-intensive areas. Bayer’s products and services are designed to benefit people and improve the quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer was founded in 1863 and is based in Leverkusen, Germany.


Deal Context for Buyer #
Overall 8 of 20
Sector: Chemicals 2 of 2
Type: Add-on Acquisition 6 of 17
Country: Argentina 1 of 1
Year: 2014 1 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2013-12-19 Algeta ASA

Oslo, Norway

Algeta ASA, an oncology company.

Buy $2.9B
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2014-05-15 Bayer HealthCare - Interventional Division

Minneapolis, Minnesota, United States

Bayer HealthCare - Interventional Division Offers a number of innovative technologies designed to treat coronary and peripheral vascular disease. The transaction includes the AngioJet Thrombectomy System and the Fetch 2 Aspiration Catheter, which use endovascular techniques to remove blood clots from blocked arteries and veins, and the JetStream Atherectomy System, a minimally invasive device used to remove plaque from diseased peripheral arteries.

Sell $415M